- Published at
- by seekingalpha.com
mixed
mixed
Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy
Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Read why I consider CTLT’s and SRPT’s revenue driven by Elevidys is not only safe.